Rafaèle Tordjman Launches JEITO CAPITAL, a New Private Equity Company Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of JEITO I at €200 Million - Seite 2

About Rafaèle Tordjman, Founder and President of Jeito Capital / Founder and President of  WITH Association

Rafaèle Tordjman, MD PhD, has been an investor in life sciences since 2001. She joined Sofinnova Partners in 2001, a Paris-based venture capital firm, as an analyst. She became co-leader and partner with €1.5 billion of assets under management, which she held until 2017.

Among other companies, Rafaèle invested in and served on the boards of DBV Technologies [DBV], Ascendis [ASND], Lysogene [LYS], MedDay, Enyo Pharma, Nucana Biomed [NCNA], ObsEva [OBSV], Flexion Therapeutics [FLXN] and Preglem, before the company was sold to Gedeon Richter.

In 2018, Rafaèle Tordjman created Jeito Capital, an independent investment company dedicated to biopharma/biotech, to establish a model of continuous financing and to invest in the next generation of leaders in medical innovation, which was approved by the Autorité des Marchés Financiers (AMF) at the end of 2019 as a portfolio management company.

Prior to joining Sofinnova Partners, Rafaèle worked as a physician and researcher in hemato-oncology. After five years working at the Hôpitaux de Paris as a medical doctor specialising in internal medicine and clinical hematology, she presented her doctoral thesis in hematology and angiogenesis, which she obtained in 2000. She then completed her post doctoral work in immunology at INSERM, Cochin Hospital, and published in Nature Biotech among others. In 2002, she also completed a management training course at INSEAD.

Driven by the idea of promoting women's entrepreneurship in healthcare, Rafaèle founded the association W.I.T.H (Women Innovating Together in Healthcare - http://with-association.com/) in 2010, and brings together more than 500 talented women from around the world who arose from medical innovation.

About JEITO CAPITAL :

Founded in 2018 and launched in January 2020 by Rafaèle Tordjman, JEITO CAPITAL, a portfolio management company approved by the Autorité des marchés financiers under number GP-19000043, is an independent investment company specialising in private equity.

JEITO CAPITAL's mission is to identify and support the next generation of pioneering entrepreneurs in the field of medical innovation, through the implementation of a continuous model of significant financing aimed at accelerating time to market.

Through its first fund, JEITO I, JEITO CAPITAL offers its investors the opportunity to support the growth of some fifteen start-ups with the potential to become future unicorns. The new investment company brings together a team of international experts in the drug value chain, combining scientific expertise, clinical development, patent protection and marketing.

Advisors:

Attorneys:
Goodwin
Arnaud David, Partner

Financial Advisors:
P&Partners (IQ EQ)
Sebastien Peru, CEO

Regulatory advisors:
Agama Conseil
Louis Gregoire Logre, Partner

Disclaimer:

This release does not constitute an offer in the United States and is intended solely for persons who are (i) not US Persons (as defined in Regulation S under the US Securities Act of 1933, as amended) and (ii) are outside of the United States.

Logo: https://mma.prnewswire.com/media/1077162/Jeito_Logo.jpg